About the Program

In 2002, Bayer HealthCare instituted the Bayer Hemophilia Awards Program with the following mission:

The Bayer Hemophilia Awards Program supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training, and other hemophilia care professionals, the program seeks to support the next steps for the next generation of care and treatment options for people with hemophilia worldwide.

Who We Are

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, with annual sales of EUR 16,913 million (2010), is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53,400 employees and is represented in more than 100 countries.

Bayer envisions the Hemophilia Awards Program as a step toward making the dream of hemophilia cures and improved treatments a reality.

The Bayer Hemophilia Awards Program demonstrates our commitment to the global bleeding disorders community and to advancing the state of the art of hemophilia care.

Research Priorities

Currently, the Program’s Research Priorities are focused on hemophilia. The program’s research priorities for the 2015/2016 cycle are as follows:

  • Patient-related, e.g. comorbidities, inhibitors, joint disease
  • Treatment-related, e.g. new products, regimens, gene therapy
  • Mechanistic, e.g. molecular mechanisms, experimental models
  • Outcomes research, e.g. patient-reported outcomes, quality of life

Previous Research

In previous award cycles the Program has provided funding to support several projects in the following areas:

  • Aspects of the molecular biology of vWF structure and function and the diagnosis and treatment of vWD
  • The function and regulation of platelets and the diagnosis of platelet disorders.

As a result, the Program will not award projects in these areas during this award cycle.

Excluded Research Topics

In order to maintain a focus on hemophilia and bleeding disorders, the Program will not support research focused on:

  • Products or technologies licensed or patented by competitors of Bayer
  • Cancer diagnosis or therapy
  • AIDS diagnosis or hepatitis therapy except where specifically related to patients with hemophilia and HIV, HCV or HBV
  • Cardiovascular disease diagnosis or therapy
  • Purely thrombotic disorders.

Dates & Deadlines

Thank you for your interest in applying for the Bayer Hemophilia Awards Program. This program represents Bayer’s continuing commitment to taking the next steps for the next generation of people with hemophilia to enjoy a better quality of life and treatment options.

Applications will be processed solely through the Internet and all applications must be submitted in English.

As a first step, applicants should submit a Letter of Intent describing the proposed project in 500 words or fewer. All Letters of Intent submitted will receive an e-mail confirming receipt.

Letters of Intent (LOI) will be reviewed by all 13 members of the Grants Review and Awards Committee. In some cases, additional information may be requested.

Selected applicants will be invited to submit a full proposal that will be reviewed by at least two members of the Grants Review and Awards Committee. These applicants will be e-mailed a full application form.

The results of the review process and funding decisions will be communicated to applicants in May each year. Funded applicants must send a letter of acceptance and enter into an agreement outlining obligations and understandings prior to disbursement of funds.

Awardees will be invited to attend an Awards Dinner that will coincide with the bi-annual meetings of the World Federation of Hemophilia (WFH) or the International Society for Thrombosis and Hemostasis (ISTH).

The table below summarizes the application timelines for 2016/17.

Action Date
LOI submissions Permitted throughout the year
Deadline for LOI consideration November 30,2016
GRAC reviews LOIs December 2016 / January 2017
GRAC informs applicants January 31, 2017
Applicants develop Full Proposals February/March 2017
Full Proposals submitted March 2017
GRAC reviews Full Proposals April/May 2017
Applicants notified of GRAC decisions May/June 2017
Funding available July/August 2017

Application Process

Letters of Intent and Full Applications are reviewed by the Grants Review and Awards Committee which comprises 13 members, representing many of the leading experts from clinical and academic medicine:

  • Alok Srivastava MD, Vellore, India (chairman)
  • Johannes Oldenburg MD, Bonn, Germany
  • Marijke van den Berg MD, Utrecht, Netherlands
  • Craig Kessler MD, Washington DC, USA
  • Riitta Lassila MD PhD, Helsinki, Finland
  • David Lillicrap MD, Kingston, Canada
  • Pier Mannucci MD, Milan, Italy
  • Michael Nichol PhD, Los Angeles, CA, USA
  • Andrea Pritchard Kennedy, PhD, RN, MN, Calgary, AB, Canada
  • Brenda Riske MS, MBA, MPA, Aurora, CO, USA
  • Midori Shima MD, Nara, Japan
  • Valder Arruda MD, Philadelphia, USA
  • Gil White MD, Milwaukee, WI, USA

All members of the Grants Review and Awards Committee will review the Letters of Intent and determine which candidates will be invited to submit full applications. Full applications will be reviewed by at least two members of the committee.

Reviewers will evaluate full applications according to the criteria outlined in the Awards section of this website. The reviewers will provide written comments and preliminary numeric scores according to these criteria.

The Committee will meet to discuss individual proposals including strengths, weaknesses and scoring. In this meeting, a consensus score for each grant application will be agreed upon. Proposals will then be ranked according to these scores in order to determine funding. In the event of identical scoring, the Committee will discuss the proposals in question and revise the scoring in order to clearly define a ranked priority. Funding will occur on a regional basis.

Three regions are defined as:

  1. United States and Canada
  2. Europe (for the purposes of this award, the Europe region includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom)
  3. Japan, China, India, Australia and all other countries.

Awards will be determined on the final priority score as agreed by the Grants Review and Awards Committee. In the event that inadequate numbers of acceptable applications are received from a particular region, additional acceptable proposals will be funded solely on the basis of priority scores, without regard to region.

The Committee’s decision is final and there is no appeal mechanism. Applicants who have constructive suggestions about the review of their applications, or the process in general, are encouraged to contact us. See Contact.

Conflict of Interest

The Program has ‘conflict of interest’ guidelines that ensure reviews are conducted in a fair and equitable manner. Reviewers will not participate in the review or priority scoring of applications in which they, or institutions with which they are affiliated, have an interest. Also, to the extent practicable, reviewers will not participate in the review of proposals competing for funding with proposals for individuals associated with their institutions.


The members of the Grants Review and Awards Committee are bound by the confidentiality rules generally applicable to such bodies.

Current Award Recipients: 2015

Fellowship Project Award

Dr Davide Matino Dr Ben Samelson-Jones
The Children’s Hospital of Philadelphia, PA, USA
Etiology of the increased activity of FIX variants with substitutions at position 338
Dr Antonino Cannavò Dr Marta Milan
Padua University Hospital, Padova, Italy
Bleeding risk profile of patients with FVII deficiency
Dr Antonino Cannavò Dr Julie Tarrant
Queens’ University, Kingston, ON, Canada
Influence of VWF on the innate immune response to FVIII
Dr Antonino Cannavò Dr Beth Warren
University of Colorado, CO, USA
Joint Outcomes Study: predictors of prophylaxis outcome

Early Career Investigator Award

Dr Juan Melero-Martin Dr Yizhou Dong
BThe Ohio State University, OH, USA
mRNA nanomedicines for treating hemophilia A
Dr Lacramioara Ivanciu Dr Behnaz Pezeshkpoor
University Clinic Bonn, Germany
Detection of domain specific inhibitors of FVIII in a large cohort of samples using a new,immunoassay
Dr Suman Sood Dr Ammon Fager
Duke University Medical Center, NC, USA
Rational Design of New Therapeutic Agents for the Treatment of Hemophilia Patients with Inhibitors
Dr Suman Sood Dr Vânia Coelho
University College of London, UK
Identification of a B cell signature associated with inhibitors in Haemophilia A

Special Project Award

Dr Brian Brown Dr Qizhen Shi
Medical College of Wisconsin, Milwaukee, WI, USA
Platelet Gene Therapy of Murine Hemophilia B with Inhibitors
Dr Francesca Fallarino Prof. Frank Buchholz
Technische Universität Dresden, Germany
Development of designer recombinases that correct factor VIII gene inversions
Dr Mettine Bos Dr Christopher Doering
Emory University, Atlanta, GA, USA
Bioengineering Factor VIII through Ancestral Reconstruction
Dr Jordan Shavit Dr Kazuo Ohashi
Osaka University, Osaka, Japan
Creation of Micro-organoids-based Cellular Therapies Toward Hemophilia

Caregiver Award

JoAnn Nilson Silvia Riva
University of Milan, Italy
RE.CO.VERY: REsponsibility for treatment COmpliance is VERY important. A study in elderly population with hemophilia
Hannie van Wanroij Hannie van Wanroij Mala Kuneeram & Urvashi Rughoo
Victoria Hospital, Quatre Bornes, Mauritius
Improving hemophilia care in Mauritius through improved laboratory diagnostic services and physiotherapy support
Dènise Bestetti Nicki Mackett
Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
Engaging Dad
Dènise Bestetti Nyondwa Zulu
Haemophilia Foundation of Zambia, Lusaka, Zambia
The impact of stigma on hemophiliacs living in the rural parts of Zambia

Outcomes Research Award

Kuixing Li Dr Michiel Coppens
Academic Medical Center, Amsterdam, The Netherlands
The role of biomarkers to predict long-term joint outcome in patients with hemophilia

Past Award Recipients